Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer

Bevacizumab is a monoclonal antibody currently used for the treatment of colorectal cancer. It works by preventing the formation of new blood vessels (angiogenesis). The drug has been shown to inhibit vascular endothelial growth factor (VEGF) activity. Previous research showed positive findings in other solid tumors that had metastasized. In this study, the investigators are investigating the response of adding bevacizumab to conventional chemotherapy for metastatic breast cancer patients.

Sex

Female

Minimum age

18 Years

Maximum age

65 Years

Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2.
* Normal left ventricular ejection fraction (LVEF).
* Age ≤ 65 years.
* At least one unidimensionally measurable lesion by imaging studies.
* AST/ALT 2.5 ULN (\< 5 ULN if liver metastases).
* Serum bilirubin 3 ULN, Serum Creatinine 1.5 ULN.
* Urine dipstick of proteinuria \<2+.
* Women of childbearing potential must have a negative serum pregnancy test.

Exclusion Criteria:

* Uncontrolled hypertension (systolic blood pressure \> 160 mm Hg, diastolic blood pressure \> 90 mm Hg).
* Prior exposure to bevacizumab.
* Planned radiotherapy for underlying disease (prior completed radiotherapy treatment allowed), except bone metastasis.
* Evidence of bleeding diathesis or coagulopathy.
* Clinically significant (i.e. active) cardiovascular disease for example cerebrovascular accidents (≤ 6 months), myocardial infarction (≤ 6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication. Stroke in the preceding six months.
* Evidence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of bevacizumab with chemotherapy.
* Ongoing treatment with aspirin (\> 325 mg/day) or other medications known to predispose to gastrointestinal ulceration.
* Pregnancy (positive serum pregnancy test) and lactation. Any other serious or uncontrolled illness which, in the opinion of the investigator, makes it undesirable for the patient to enter the trial.

• BACKGROUNDMiller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol. 2001 Feb 15;19(4):1195-206. doi: 10.1200/JCO.2001.19.4.1195. PMID 11181686
• BACKGROUNDMoy B, Goss PE. Lapatinib: current status and future directions in breast cancer. Oncologist. 2006 Nov-Dec;11(10):1047-57. doi: 10.1634/theoncologist.11-10-1047. PMID 17110623
• BACKGROUNDChu E. Bevacizumab targeted therapy: validation of angiogenesis as a key target for advanced colorectal cancer. Clin Colorectal Cancer. 2004 May;4(1):16. doi: 10.3816/ccc.2004.n.006. No abstract available. PMID 15207014
• BACKGROUNDEniu A. Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab. J BUON. 2007 Sep;12 Suppl 1:S119-26. PMID 17935269
• BACKGROUNDCaprioni F, Fornarini G. Bevacizumab in the treatment of metastatic colorectal cancer. Future Oncol. 2007 Apr;3(2):141-8. doi: 10.2217/14796694.3.2.141. PMID 17381413
• BACKGROUNDJubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, Kabbinavar F, Holden SN, Novotny WF, Frantz GD, Hillan KJ, Koeppen H. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol. 2006 Jan 10;24(2):217-27. doi: 10.1200/JCO.2005.01.5388. Epub 2005 Dec 19. PMID 16365183
• BACKGROUNDLink JS, Waisman JR, Nguyen B, Jacobs CI. Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer. Clin Breast Cancer. 2007 Oct;7(10):779-83. doi: 10.3816/CBC.2007.n.039. PMID 18021479